Skip to main content
Sandoz Group AG logo

Sandoz Group AG — Investor Relations & Filings

Ticker · SDZ ISIN · CH1243598427 LEI · 5493000JWK6XWFEUD320 SW Manufacturing
Open in API
Filings indexed 78 across all filing types
Latest filing 2025-12-01 Regulatory Filings
Country CH Switzerland
Listing SW SDZ

About Sandoz Group AG

https://www.sandoz.com/

Sandoz Group AG is a global leader in generic and biosimilar medicines. The company's core activities involve the development, manufacturing, and distribution of off-patent pharmaceuticals to increase patient access to healthcare. Its business operates through two primary segments: Generics, which covers a wide range of small-molecule drugs, and Biosimilars, which are approved versions of original biologic medicines. Sandoz provides treatments for various diseases, including cancer and diabetes, and its product portfolio also includes key medicines such as antibiotics. The company's stated purpose is to pioneer access to medicines for patients worldwide.

Recent filings

Filing Released Lang Actions
Sandoz launches denosumab biosimilars in Europe, providing affordable treatment option for cancer-related bone disease and osteoporosis for millions of patients
Regulatory Filings Classification · 100% confidence The document is an 'ad hoc announcement' regarding the market launch of new biosimilar products (Wyost and Jubbonti) by Sandoz Group AG. It follows the standard format for a regulatory news release (RNS) issued via the EQS News Service, providing details on product approvals, strategic growth, and contact information. It does not fit into specific categories like financial reports, proxy statements, or director dealings, making 'Regulatory Filings' (RNS) the most appropriate classification.
2025-12-01 English
Sandoz launches Afqlir (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Regulatory Filings Classification · 100% confidence The document is an 'ad hoc' announcement from Sandoz Group AG regarding the market launch of a new product (Afqlir). It follows the standard format for regulatory news service (RNS) announcements, including the 'Inside Information' header, the SIX Swiss Exchange listing rules reference, and contact information. It is not a full financial report, presentation, or legal proceeding, but rather a corporate regulatory disclosure of a business development event.
2025-11-24 English
Sandoz launches Afqlir® (aflibercept) in Europe, providing affordable treatment option for patients with retinal diseases
Regulatory Filings Classification · 100% confidence The document is an 'Ad hoc announcement' regarding the market launch of a new product (Afqlir) by Sandoz Group AG. It follows the standard format for regulatory news service (RNS) announcements, including an EQS News ID, ISIN, and listing information. It is not a financial report, transcript, or presentation, but rather a corporate announcement of a business development event, which falls under the Regulatory Filings (RNS) category.
2025-11-24 English
Sandoz launches TYRUKO (natalizumab-sztn) in US, as first and only multiple sclerosis biosimilar
Regulatory Filings Classification · 100% confidence The document is an 'ad hoc announcement' regarding the market launch of a new product (TYRUKO) by Sandoz Group AG. It follows the standard format of a regulatory news release (RNS) issued via the EQS News Service, providing details on product approval, commercialization, and safety information. It does not constitute a full financial report, transcript, or presentation, but rather a corporate announcement of a business development event.
2025-11-17 English
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
M&A Activity Classification · 100% confidence The document is a press release announcing a new global license agreement between Sandoz and EirGenix Inc. to commercialize a biosimilar. It details the strategic partnership, financial terms (milestone-based payments), and the impact on the company's oncology portfolio. As this is a corporate announcement regarding a business development/partnership agreement that does not fit into specific categories like M&A (which usually implies full mergers or takeovers) or capital raising, it falls under the general regulatory announcement category.
2025-11-12 English
Sandoz signs global license agreement to commercialize breast cancer biosimilar pertuzumab
M&A Activity Classification · 100% confidence The document is a press release from Sandoz Group AG announcing a new global license agreement with EirGenix Inc. to commercialize a biosimilar of pertuzumab. It details the financial terms (USD 152 million), the strategic rationale, and the impact on their oncology portfolio. Since this document describes a specific business transaction (a licensing agreement) rather than a recurring financial report, a management change, or a regulatory filing, it falls under the 'Regulatory Filings' (RNS) category as a general corporate announcement.
2025-11-12 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.